VAR2 Pharmaceuticals co-authors have published an article in Nature Communications entitled “Cryo-EM reveals the architecture of placental malaria VAR2CSA and provides molecular insight into chondroitin sulfate binding”. This article reports the high-resolution structure of our proprietary cancer targeting molecule, VAR2CSA, and sheds light on the complex interaction between VAR2CSA and oncofetal chondroitin sulfate in tumors and placenta. The long and stretched interaction between the two molecules explains how VAR2CSA can bind with such high affinity and specificity to oncofetal chondroitin sulfate.
 

Read more: